| Name | IDO5L |
| Description | IDO5L (INCB024360 analogue) is an effective IDO1 inhibitor(IC50=10 nM). |
| In vitro | In an immunologically active mouse model, INCB024360 effectively inhibited tumor growth. Similarly, in mice bearing GM-CSF-secreting B16 tumors, INCB024360 (75 mg/kg b.i.d) demonstrated dose-dependent tumor growth suppression. |
| In vivo | INCB024360 significantly inhibits IDO1 in HeLa cells (IC50 = 19 nM) and promotes differentiation in CD4+ T cells, CD8+ T cells, and NK cells. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 5 mg/mL (18.41 mM) Ethanol : 27.2 mg/mL (100.13 mM), Sonication is recommended. DMSO : 50 mg/mL (184.07 mM)
|
| Keywords | Inhibitor | inhibit | Indoleamine2,3Dioxygenase(IDO) | Indoleamine2,3Dioxygenase | Indoleamine 2,3-Dioxygenase (IDO) | Indoleamine 2,3Dioxygenase (IDO) | Indoleamine 2,3-Dioxygenase | INCB-14943 | INCB 14943 | IDO-5L | IDO5L | IDO1 | IDO |
| Inhibitors Related | Palmatine chloride | GNF-PF-3777 | Necrostatin-1 | IDO-IN-7 | TDO-IN-1 | IDO1-IN-28 | Indoximod | Palmatine | Epacadostat | β-Lapachone | IDO-IN-12 | 3-TYP |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | ReFRAME Related Library | Anti-Cancer Metabolism Compound Library | Inhibitor Library | NO PAINS Compound Library | Immuno-Oncology Compound Library | Metabolism Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Metabolism Disease Compound Library |